StemCellPatents.com Newsletter
Your weekly source for the latest stem cell research and stem cell patents.
Dear manoj kumar valluru,
Last week the San Diego company Cytori published data demonstrating high content of stem cells in adipose tissue processed with their proprietary Celution Device. Interestingly, a key patent for this device #7,390,484 (patent spotlight) was also issued. Although there have been some discussions regarding composition of matter claims on adipose derived stem cells by a competing group, the fact Cytori is actually clinically implimenting its IP, we believe, positions the company ahead of detractors.
Other events included publication of double blind trial data on critical limb ischemia using genetic delivery of HGF-1. Although improvement in transcutaneous oxygen was observed, no benefit in other parameters, like pain free walking distance, pain score, ABI, etc was observed. We at StemCellPatents.com have always supported the view that "cytokine factory" approach of administering stem cells for diseases like critical limb ischemia is always philosophically more attractive than single agent approaches. With that said we which Aldagen all the best for its filed IPO.
Supporting the view that cancer stem cells really do exist, a clinical publication demonstrated a "self renewal", cancer stem cell-like gene profile correlates with poor prognosis in glioma patients.
Newly issued patents last week included #7,390,619 which covers ways of optimizing a genetic vaccine by mutating CD80 molecules to get higher affinity for CD28 and lower for CTLA-4, as well as # 7,390,658 which covers ways of generating lymphoid dendritic cells from blood CD34s.
|
|
|
|
As always, we welcome your comments on what you would like to see on StemCellPatents.com! Tell us here.
Thanks again for your help in supporting StemCellPatents.com.
(BETA)